Quick Answer
Satellos Bioscience Inc. reported operating profit of -$26.46 million for fiscal year 2025, reported under IFRS on Form 20-F.
Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted.
Satellos Bioscience Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating Profit | -$26.46M -29.7% |
-$20.40M | — |
| Net Income | -$24.87M -20.5% |
-$20.63M | — |
| Basic EPS | -$1.70 +21.3% |
-$2.16 | — |
| Diluted EPS | -$1.70 +21.3% |
-$2.16 | — |
| Total Assets | $31.89M -37.2% |
$50.75M +51.5% |
$33.49M |
| Total Liabilities | $4.11M +14.6% |
$3.58M +31.1% |
$2.73M |
| Total Equity | $27.78M -41.1% |
$47.16M +53.3% |
$30.76M |
| Operating Cash Flow | -$23.60M -29.3% |
-$18.25M | — |
| R&D Expense | $18.43M +28.3% |
$14.36M | — |
- Satellos Bioscience Inc. reported operating profit of -$26.46 million for fiscal year 2025.
- That is a decrease of -29.7% versus the prior fiscal year.
- Satellos Bioscience Inc. reported net income of -$24.87 million for fiscal year 2025.
- That is a decrease of -20.5% versus the prior fiscal year.
- Satellos Bioscience Inc. reported basic eps of $-1.70 per share for fiscal year 2025.
- That is an increase of +21.3% versus the prior fiscal year.
- Satellos Bioscience Inc. reported diluted eps of $-1.70 per share for fiscal year 2025.
- That is an increase of +21.3% versus the prior fiscal year.
- Satellos Bioscience Inc. reported total assets of $31.89 million for fiscal year 2025.
- That is a decrease of -37.2% versus the prior fiscal year.
- Satellos Bioscience Inc. reported total liabilities of $4.11 million for fiscal year 2025.
- That is an increase of +14.6% versus the prior fiscal year.
- Satellos Bioscience Inc. reported total equity of $27.78 million for fiscal year 2025.
- That is a decrease of -41.1% versus the prior fiscal year.
- Satellos Bioscience Inc. reported operating cash flow of -$23.60 million for fiscal year 2025.
- That is a decrease of -29.3% versus the prior fiscal year.
- Satellos Bioscience Inc. reported r&d expense of $18.43 million for fiscal year 2025.
- That is an increase of +28.3% versus the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 19, 2026.
Last verified: